width=IntraBio, a UK-based biopharmaceutical company, has received approval from the US Food and Drug Administration to run a clinical trial in patients who have Ataxia-Telangiectasia (A-T). The company will test their investigational new drug, IB1001, an orally-administered version of N-Acetyl-L-Leucine, to evaluate its safety and efficacy in improving symptoms, functioning, and quality of life.

N-Acetyl-L-Leucine is the active ingredient in N-Acetyl-DL-Leucine, a modified amino acid that has been approved in France since 1957 for the treatment of vertigo. More recently, papers have been published reporting efficacy of N-Acetyl-DL-Leucine in some other cerebellar ataxias.

IntraBio is now planning to run an open-label, blinded-rater trial using three clinical sites to test this drug in A-T patients, one site in the US and two in Europe, recruiting approximately 10 participants per site. The company expects to start later this year, testing the drug in US patients who are at least 18 years of age and UK/European patients at least six years of age.

More details on this trial can be found at clinicaltrials.gov

Contact Us

Related News

May 21 @ 5:47 am

Shining a Light on A-T at the IlluminATion Ball

The A-TCP is hosting IlluminATion: A BioPharma Leadership Ball on May 11 in Boston to shine a light

more
May 21 @ 5:47 am

NEAT Study – Phase 3 Clinical Trial of EryDex, a Low-Dose Steroid

Quince Therapeutics is advancing a phase 3 clinical trial to evaluate EryDex, a potential new treatment for ataxia-telangiectasia

more
May 21 @ 5:47 am

Measles Prevention in A-T: Recommendations from Dr. Lederman

Dr. Lederman of the A-T Clinical Center provides recommendations to keep people with A-T from catching measles.

more
May 21 @ 5:47 am

Looking Forward to Research Advances in 2024

As 2023 is wrapping up, we want to thank all of you who support the A-T Children’s Project

more